Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2007

01-06-2007 | CASE REPORT

Pneumocystis Pneumonia During Combined Therapy of Infliximab, Corticosteroid, and Azathioprine in a Patient with Crohn’s Disease

Authors: Soichi Itaba, Tsutomu Iwasa, Yojiro Sadamoto, Toshifumi Nasu, Tadashi Misawa, Koji Inoue, Hidehiko Shimokawa, Kazuhiko Nakamura, Ryoichi Takayanagi

Published in: Digestive Diseases and Sciences | Issue 6/2007

Login to get access

Excerpt

Pneumocystis pneumonia (PCP) is one of the most frequent and severe opportunistic infections in immunocompromised patients. In recognition of its genetic and functional distinctiveness, the organism that causes human PCP has now been designated Pneumocystis jiroveci [1]. …
Literature
1.
Stringer JR, Beard CB, Miller RF, Wakefield AE (2002) A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 8:891–890PubMed
2.
Sepkowiz KA (2002) Opportunistic infestions in patients with and patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 34:1098–1107CrossRef
3.
Roblot F (2005) Management of Pneumocystis pneumonia in patients with inflammatory disorders. Expert Rev Anti Infect Ther 3:435–444PubMedCrossRef
4.
Ward MM, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42:780–789PubMedCrossRef
5.
Peters JW, Sattler FR (1983) Atypical Pneumonitis carinii pneumonia: the potential hazards of empric treatment. South Med J 76:800–803PubMed
6.
Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, Ghrayeb J (1993) Construction and initial characteraization a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443–1453PubMedCrossRef
7.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 359:1541–1549PubMedCrossRef
8.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476PubMedCrossRef
9.
Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck SD, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19–31PubMedCrossRef
10.
Sandborn WJ, Hanauer SB (2002) Infliximab in the treatment of Crohn’s disease: a user’s guide for clinician’s. Am J Gastroenterol 97:2962–2972PubMedCrossRef
11.
Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF (2004) Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease. Inflamm Bowel Dis 10:436–437PubMedCrossRef
12.
Velayos FS, Sandborn WJ (2004) Pneumocystisis carinii pneumonia during maintenance anti-tumor necrosis factor-a therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 10:657–660PubMedCrossRef
13.
Kaur N, Mahl TC (2004) Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn’s disease. Dig Dis Sci 49:1458–1460PubMedCrossRef
14.
Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S (1996) (1→3)Beta-D-glucan as a quantitive serological marker for Pneumocystis pneumonia. Clin Diagn Lab Immunol 3:197–199PubMed
15.
Sepkowitz KA, Brown AE, Armstrong D (1995) Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk. Arch Intern Med 155:1125–1128PubMedCrossRef
16.
Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M (2002) Review article: the management of refractory Crohn’s disease. Aliment Pharmacol Ther 16:40–47PubMedCrossRef
17.
Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Meyer zum Buschenfelde KH (1993) Azathioprine combined with predonisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 105:367–372PubMed
18.
Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 15:132–142
19.
Fraser AG, Orchard TR, Jewell DP (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50:485–489PubMedCrossRef
20.
Khatchatourian M, Seaton TL (1997) An unusual complication of immunosuppressive therapy in inflammatory bowel disease. Am J Gastroenterol 92:1558–1560PubMed
21.
Cohen RD, Tsang JF, Hanauer SB (2000) Infliximab in Crohn’s disease: first anniversary clinical experience. Am J Gastroenterol 95:3469–3477PubMedCrossRef
22.
Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, Dellion S, Rossert J, Rostoker G, Piette JC, Schaeffer A (1994) Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 21:246–251PubMed
23.
24.
Wazir JF, Ansari NA (2004) Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med 128:1023–1027PubMed
25.
Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med 337:1029–1035PubMedCrossRef
26.
Pareja JG, Garland R, Kozeil H (1998) Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 113:1215–1224PubMed
Metadata
Title
Pneumocystis Pneumonia During Combined Therapy of Infliximab, Corticosteroid, and Azathioprine in a Patient with Crohn’s Disease
Authors
Soichi Itaba
Tsutomu Iwasa
Yojiro Sadamoto
Toshifumi Nasu
Tadashi Misawa
Koji Inoue
Hidehiko Shimokawa
Kazuhiko Nakamura
Ryoichi Takayanagi
Publication date
01-06-2007
Published in
Digestive Diseases and Sciences / Issue 6/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9575-5

Other articles of this Issue 6/2007

Digestive Diseases and Sciences 6/2007 Go to the issue

Original Paper

Effect of Calcium Polycarbophil on Bowel Function After Restorative Proctocolectomy for Ulcerative Colitis: A Randomized Controlled Trial

Case Report

Hyperamylasemia, Reactive Plasmacytosis, and Immune Abnormalities in a Patient with Celiac Disease

Case Report

Serology- and Biopsy-Proven Celiac Disease in a Patient with AIDS: Case Report

Original Paper

Salt and Stress Synergize H. pylori-Induced Gastric Lesions, Cell Proliferation, and p21 Expression in Mongolian Gerbils

Original Paper

Nimesulide Alters Cell Recruitment into Mitosis in Murine Intestinal Crypts Without Influencing the Cell Production Rate

Original Paper

Da-Cheng-Qi-Tang Promotes the Recovery of Gastrointestinal Motility After Abdominal Surgery in Humans
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits